TCEB2 confers resistance to VEGF-targeted therapy in ovarian cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Anti-VEGF therapy, including bevacizumab (BV), is approved for ovarian cancer (OC).
• Resistance to anti-VEGF therapy limits its efficacy in OC, with underlying mechanisms unclear.
• Understanding resistance is crucial for developing more effective OC treatments.

Purpose of the Study:

• To elucidate the molecular mechanisms of acquired resistance to bevacizumab (BV) in ovarian cancer (OC).
• To identify novel therapeutic targets for overcoming BV resistance in OC.
• To evaluate a combination therapy strategy for advanced OC.

Main Methods:

• Utilized xenograft models to study differential responses of OC cells to bevacizumab (BV).
• Performed gene expression analysis to identify key genes involved in BV resistance.
• Conducted mechanistic studies to determine the role of TCEB2 and IL-8 in OC resistance.

Main Results:

• TCEB2 was significantly upregulated in BV-resistant OC tumors.
• TCEB2 promoted BV resistance by enhancing HIF-1α degradation and reducing VEGF-A expression.
• Overexpression of TCEB2 led to elevated IL-8, which acted as a compensatory angiogenesis signal.
• Combination therapy with BV and IL-8 monoclonal antibody (IL-8 Ab) showed synergistic growth inhibition in OC and endothelial cells.

Conclusions:

• TCEB2 is a critical mediator of acquired resistance to BV in OC.
• IL-8 acts as a compensatory angiogenesis pathway in TCEB2-overexpressing OC cells.
• Simultaneous targeting of VEGF-A and IL-8 presents a promising therapeutic strategy for OC.